Diabetic peripheral neuropathy (DPN) is the most common chronic complication of diabetes, affecting roughly half of all people living with the disease over their lifetime. Because it progressively erodes protective sensation in the feet, DPN is the central pathway leading to foot ulceration, infection, and lower-limb amputation. Yet in routine practice it is frequently identified only at a late, often pre-ulcerative stage. Understanding why early detection matters, and how screening tools differ in what they can actually detect, is essential for clinicians, patients, and caregivers alike.
Why Early Detection Changes Outcomes
DPN typically begins in the smallest, most distal nerve fibres and advances proximally in a length-dependent, “stocking” distribution. Early changes affect the small unmyelinated and thinly myelinated fibres that carry pain and temperature signals, often before the large fibres responsible for vibration and touch are measurably impaired. The clinical consequence is that a person may lose the early-warning sensations that normally prompt them to shift weight, notice a blister, or feel a pebble in a shoe long before standard bedside tests turn abnormal.
The stakes are well quantified. A 2023 systematic review and meta-analysis of risk factors for diabetic foot ulcers found that comorbid neuropathy carried one of the strongest associations of any variable studied, with an odds ratio of roughly 4.8 for ulcer development (Tang and colleagues, Vascular, 2023). Once protective sensation is lost, minor trauma can progress silently to a deep ulcer. This is why authoritative reviews emphasise that prevention must begin upstream, with reliable identification of nerve damage before the skin breaks down.
The Limits of Conventional Screening
Most diabetic foot screening still relies on the 10-gram Semmes-Weinstein monofilament, often paired with a 128-Hz tuning fork. These tools are inexpensive, portable, and validated for predicting ulcer risk. Their important limitation is one of timing: they primarily assess large-fibre function and identify neuropathy only once it is relatively advanced. As Burgess and colleagues argued in a 2021 review in Diagnostics, the monofilament detects loss of protective sensation rather than early disease, leaving a gap between the onset of small-fibre injury and the point at which standard screening becomes positive. The authors contrasted this with the success of structured diabetic eye and kidney screening programmes and highlighted the unmet need for an objective, reproducible biomarker of early DPN.
Clinical guidance has responded by emphasising frequency and structure rather than any single test. General-practice reviews recommend that every person with diabetes receive at least an annual foot assessment, with more frequent review, every three to six months, for those with established neuropathy, peripheral arterial disease, or a prior ulcer (Reardon and colleagues, Australian Journal of General Practice, 2020). The International Working Group on the Diabetic Foot (IWGDF) risk-stratification framework formalises this by sorting patients into escalating risk categories that determine how often the feet should be examined.
Emerging Diagnostic Tools
A major direction in recent research is the detection of small-fibre damage, which precedes large-fibre loss. Corneal confocal microscopy (CCM), a rapid and non-invasive imaging technique, allows direct quantification of small corneal nerve fibres and has been shown to identify sub-clinical DPN, predict its development, and stage its severity. Burgess and colleagues noted that CCM can be performed alongside retinal screening and that automated, artificial-intelligence-assisted analysis is improving its reproducibility. A 2025 review in Signal Transduction and Targeted Therapy by Yang and colleagues similarly highlighted CCM and biomarker-based tests as advances improving early detection, while cautioning that disease-modifying treatments remain elusive and that current management still centres on glycaemic control, risk-factor modification, and symptom relief.
Point-of-care nerve conduction devices and home-based pressure and temperature monitoring systems are also being explored to extend screening into community and resource-limited settings. These approaches are promising for accessibility, though several still concentrate on large-fibre function or remain at the prototype stage and require further validation before routine adoption.
The Role of Patient Understanding
Detection tools only translate into prevention when patients act on their results. A 2024 study in the Journal of the American Podiatric Medical Association by Garcia-Madrid and colleagues, which assessed knowledge across IWGDF risk levels, found that the highest-risk patients understood the natural progression of foot complications and how to prevent them better than lower-risk patients did. The authors concluded that education efforts should be directed earlier, toward lower-risk individuals, rather than waiting until advanced disease prompts attention. A key insight is that a neuropathic ulcer is typically painless, which can falsely reassure patients who equate absence of pain with absence of danger.
Key Takeaways
Diabetic peripheral neuropathy is common, progressive, and a leading antecedent of foot ulceration and amputation. Conventional monofilament and tuning-fork screening reliably flag advanced, large-fibre neuropathy but miss the earliest small-fibre changes. Structured, risk-based surveillance, at least annually and more often for higher-risk feet, remains the practical foundation of care, while emerging tools such as corneal confocal microscopy and small-fibre biomarkers may eventually close the early-detection gap. Throughout, patient education and the recognition that loss of sensation, not pain, signals danger are central to preventing the complications that early detection is meant to avert.
References
Burgess J, Frank B, Marshall A, et al. Early Detection of Diabetic Peripheral Neuropathy: A Focus on Small Nerve Fibres. Diagnostics (Basel). 2021;11(2):165.
Yang Y, Zhao B, Wang Y, et al. Diabetic neuropathy: cutting-edge research and future directions. Signal Transduction and Targeted Therapy. 2025;10(1):132.
Tang WH, Zhao YN, Cheng ZX, et al. Risk factors for diabetic foot ulcers: A systematic review and meta-analysis. Vascular. 2023;32(3):661-669.
Reardon R, Simring D, Kim B, et al. The diabetic foot ulcer. Australian Journal of General Practice. 2020;49(5):250-255.
Garcia-Madrid M, Lopez-Moral M, Tardaguila-Garcia A, et al. Disease Knowledge and Behavior Regarding the Diabetic Foot in Persons at Different Risks for Foot Ulceration According to the IWGDF Guidelines. Journal of the American Podiatric Medical Association. 2024;114(5).
Comments
